Background: Stroke is the second leading cause of death worldwide and remains an important health burden both for the individuals and for the national healthcare systems. Potentially modifiable risk factors for stroke include hypertension, cardiac disease, diabetes, and dysregulation of glucose metabolism, atrial fibrillation, and lifestyle factors. Objects: We aimed to derive a model equation for developing a stroke pre-diagnosis algorithm with the potentially modifiable risk factors. Methods: We used logistic regression for model derivation, together with data from the database of the Korea National Health Insurance Service (NHIS). We reviewed the NHIS records of 500,000 enrollees. For the regression analysis, data regarding 367 stroke patients were selected. The control group consisted of 500 patients followed up for 2 consecutive years and with no history of stroke. Results: We developed a logistic regression model based on information regarding several well-known modifiable risk factors. The developed model could correctly discriminate between normal subjects and stroke patients in 65% of cases. Conclusion: The model developed in the present study can be applied in the clinical setting to estimate the probability of stroke in a year and thus improve the stroke prevention strategies in high-risk patients. The approach used to develop the stroke prevention algorithm can be applied for developing similar models for the pre-diagnosis of other diseases.

1.
Hong KS, Bang OY, Kang DW, Yu KH, Bae HJ, Lee JS, Heo JH, Kwon SU, Oh CW, Lee BC, Kim JS, Yoon BW: Stroke statistics in Korea: part I. Epidemiology and risk factors: a report from the Korean stroke society and clinical research center for stroke. J Stroke 2013; 15: 2–20.
2.
Oh CM, Won YJ, Jung KW, et al: Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2013. Cancer Res Treat 2016; 48: 436–450.
3.
Clinical Research Center for Stroke. Clinical Practice Guidelines for Stroke, ed 3. Korea, 2015.
4.
Organization for Economic Co-operation and Development: OECD Reviews of Health Care Quality OECD Reviews of Health Care Quality: Korea 2012: Raising Standards; In: OECD Reviews of Health Care Quality. Paris, OECD Publish Inger, 2012, p 146.
5.
Siegler JE, Boehme AK, Kumar AD, Gillette MA, Albright KC, Beasley TM, Martin-Schild S: Identification of modifiable and nonmodifiable risk factors for neurologic deterioration after acute ischemic stroke. J Stroke Cerebrovasc Dis 2013; 22:e207–e213.
6.
Brown RD, Whisnant JP, Sicks JD, O’Fallon WM, Wiebers DO: Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke 1996; 27: 373–380.
7.
Wolf PA, D’agostino RB, O’neal MA, Sytkowski P, Kase CS, Belanger AJ, Kannel WB: Secular trends in stroke incidence and mortality. The Framingham Study. Stroke 1992; 23: 1551–1555.
8.
Association AH: Heart Disease and Stroke Statistics-2004 Update. American Heart Association. Dallas, TX, 2003.
9.
Lawlor DA, Ronalds G, Clark H, Smith GD, Leon DA: Birth weight is inversely associated with incident coronary heart disease and stroke among individuals born in the 1950s: findings from the Aberdeen Children of the 1950s prospective cohort study. Circulation 2005; 112: 1414–1418.
10.
Lewington S: Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2003; 360: 1903–1913.
11.
Psaty BM, Lumley T, Furberg CD: Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289: 2534–2544.
12.
Shinton R, Beevers G: Meta-analysis of relation between cigarette smoking and stroke. BMJ 1989; 298: 789–794.
13.
Bonita R, Duncan J, Truelsen T, Jackson RT, Beaglehole R: Passive smoking as well as active smoking increases the risk of acute stroke. Tob Control 1999; 8: 156–160.
14.
You RX, Thrift AG, McNeil JJ, Davis SM, Donnan GA: Ischemic stroke risk and passive exposure to spouses’ cigarette smoking. Melbourne Stroke Risk Factor Study (MERFS) Group. Am J Public Health Res 1999; 89: 572–575.
15.
Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983–988.
16.
Goldstein LB, Adams R, Alberts MJ, et al: Primary prevention of ischemic stroke: a guideline from the American heart association/American stroke association stroke council: Cosponsored by the atherosclerotic peripheral vascular disease interdisciplinary working group; cardiovascular nursing council; clinical cardiology council; nutrition, physical activity, and metabolism council; and the quality of care and outcomes research interdisciplinary working group: the American academy of neurology affirms the value of this guideline. Stroke 2006; 37: 1583–1633.
17.
Stratton IM, Adler AI, Neil HA, et al: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405–412.
18.
Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685–696.
19.
Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, Jensvold NG, Selby JV, Singer DE: Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003; 290: 2685–2692.
20.
van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, Koudstaal PJ, Chang Y, Hellemons B: Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002; 288: 2441–2448.
21.
Hart RG, Benavente O, McBride R, Pearce LA: Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492–501.
22.
Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ: Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864–2870.
23.
Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, Petersen P: Selecting patients with atrial fibrillation for anticoagulation. Circulation 2004; 110: 2287–2292.
24.
Mohr J, Grotta JC, Wolf PA, Moskowitz MA, Mayberg MR, Von Kummer R: Stroke E-Book: Pathophysiology, Diagnosis, and Management: Elsevier Health Sciences, 2011.
25.
Amarenco P, Labreuche J, Lavallée P, Touboul PJ: Statins in stroke prevention and carotid atherosclerosis. Stroke 2004; 35: 2902–2909.
26.
Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N: Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 49–57.
27.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321–233.
28.
Song YM, Sung J, Davey Smith G, Ebrahim S: Body mass index and ischemic and hemorrhagic stroke. Stroke 2004; 35: 831–836.
29.
Kurth T, Gaziano JM, Berger K, Kase CS, Rexrode KM, Cook NR, Buring JE, Manson JE: Body mass index and the risk of stroke in men. Arch Intern Med 2002; 162: 2557–2562.
30.
Folsom AR, Prineas RJ, Kaye SA, Munger RG: Incidence of hypertension and stroke in relation to body fat distribution and other risk factors in older women. Stroke 1990; 21: 701–706.
31.
Suk SH, Sacco RL, Boden-Albala B, Cheun JF, Pittman JG, Elkind MS, Pail MC: Abdominal obesity and risk of ischemic stroke. Stroke 2003; 34: 1586–1592.
32.
Cho NH, Kim KM, Choi SH, Park KS, Jang HC, Kim SS, Sattar N, Lim S: High blood pressure and its association with incident diabetes over 10 years in the Korean Genome and Epidemiology Study (KoGES). Diabetes Care 2015; 38: 1333–1338.
33.
Lee HY, Park JB: The Korean Society of Hypertension Guidelines for the management of hypertension in 2013: its essentials and key points. Pulse 2015; 3: 21–28.
34.
Korean Diabetes Association (KDA): Treatment guideline for diabetes. J Korean Diabetes 2011; 12:S1–S244.
35.
Korean Academy of Medical Sciences (KAoM): Evidence-based Recommendations for Dyslipidemia in Primary Care. Korea, 2017.
36.
Park JH, Jo MS: NCEP (National Cholesterol Education Program) expert panel on detection, evaluation, and treatement of high blood cholesterol in adults (ATP III). Korean J Lipidol 2001; 11: 420–429.
37.
Salihu HM, Bonnema SM, Alio AP: Obesity: what is an elderly population growing into? Maturitas 2009; 63: 7–12.
38.
Han NY, Ko EA, Hwang SY: Knowledge of stroke symptoms and risk factors among older adults. Korean J Adult Nurs 2009; 21: 314–323.
39.
Park TH, Kim MK, Lee KB, Park JM, Lee SJ, Jung KH, Cho YJ, Lee JS, Lee j, Bae HJ: Prevalence of risk factors for ischemic stroke in Korean: a systematic review. J Korean Neurol Assoc 2009; 27: 19–27.
40.
Mackay J, Mensah GA, Mendis S, Greenlund K: The Atlas of Heart Disease and Stroke. World Health Organization, 2004.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.